吡喹酮，Praziquantel [PZQ]；Pharmaceutical Secondary Standard; Certified Reference Material

Praziquantel is at present the only drug used for the treatment of human schistosomiasis. It has a pyrazino isoquinoline ring system and is found to be very successful in animals for its anticestode and antitrematode properties. It has been identified that the voltage-gated schistosome calcium ion (Ca²⁺) channels serve as a target for praziquantel. Even though the commercial preparation of praziquantel comprises of equal amounts of both its ‘dextro′ and ‘laevo′ isomers, only the ‘laevo′ form exhibits schistosomicidal activity.
Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.

 

Praziquantel may be used as a pharmaceutical reference standard in the determination of the analyte in pharmaceutical preparations by electrochemical, spectrophotometric, and chromatographic techniques.

These Secondary Standards are qualified as Certified Reference Materials. These are suitable for use in several analytical applications including but not limited to pharma release testing, pharma method development for qualitative and quantitative analyses, food and beverage quality control testing, and other calibration requirements.

 

To see an example of a Certificate of Analysis for this material enter LRAA1898 in the slot below. This is an example certificate only and may not be the lot that you receive.